Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, D…
Industry Peers
Drug Manufacturers - General| Headline | Source | Time |
|---|---|---|
Yesterday | ||
 Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy? In August 2026, Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead's global antibody-drug conjugate clinical development programs across multiple oncology indications. The partnership highlights how integrating AI-native computational pathology with clinical outcomes may help standardize biomarker assessment and refine precision medicine efforts in Gilead's oncology portfolio. Next, we'll examine how... | ||
This week | ||
 Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022 These stocks can be safe-haven investments to hide out in amid market turmoil. | ||
 Biotech Stocks Are Booming. What This Top Fund Is Buying Now. Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3% | ||
 Is Gilead's Expanding HIV Portfolio a Growth Catalyst? Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects. | ||
 Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs. | ||
 Gilead yanks out a thorn in its side in major court ruling A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the company's revenue. The decision blocks a group of companies from importing cheaper foreign versions of Gilead's top HIV drug and selling them to American patients. For a company that relies heavily on a ... | ||
 Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500’s 13.1% gain. This might have investors contemplating their next move. | SStockStory | |
Older | ||
 Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)’s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies’ 2022 collaboration. That broader agreement spans three programs, including clinical-stage CD123 x CD3 […] | IInsider Monkey | |
 Gilead wins appeals court ruling against overseas drug imports A federal appeals court ruled Thursday that international versions of Gilead's HIV drug Biktarvy differ materially from FDA-regulated U.S. versions | ||
 BofA biotech scorecard: Two buys and odd one out Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ... | ||
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across […] | IInsider Monkey | |
Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of that progress is now priced into the... | ||
Why Gilead Sciences (GILD) Is Back In The Spotlight Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder returns are above 90%... | ||
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches—including Trodelvy in breast cancer and Livdelzi in liver disease—for boosting results. CEO Daniel O’Day highlighted, “Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time,” underscoring the im | SStockStory | |